Group 1 - The Hang Seng Biotechnology Index and the Hang Seng Hong Kong Stock Connect Innovative Drug and Healthcare Index will incorporate a volatility screening for biotech companies whose stock names end with "B" that are not constituent stocks [1] - This adjustment will be implemented in the index review as of December 31, 2025, and the changes will take effect on March 9, 2026 [1] - The index names and codes will remain unchanged despite the adjustments [1]